MRKMerck Sharp & Dohme LLCFinished
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
Small Cell Lung Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 122 (final count)
- Started
- Jul 15, 2021
- Main results expected
- Jun 23, 2025
- Fully finished
- Jun 23, 2025
- Results posted
- Jul 1, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Measured over: Up to approximately 43 months
Six-Month Progression-Free Survival (PFS) Rate as Assessed by BICR Per RECIST 1.1
Measured over: At 6 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04924101 · record last updated 2026-08-13 · checked 2026-11-09 15:47 UTC